Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ado-trastuzumab emtansine + osimertinib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Ado-trastuzumab emtansine + osimertinib is an investigational drug combination consisting of two targeted therapies: ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, and osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This combination was studied primarily in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who developed resistance to EGFR inhibitors associated with HER2 overexpression. The rationale for this regimen is dual blockade of EGFR and HER2 pathways to overcome acquired resistance mechanisms. Clinical trials have shown that while the safety profile is favorable compared to cytotoxic chemotherapy, efficacy has been limited, with low response rates and short progression-free survival[1][2][3][5].
- Brand names
- Kadcyla + Tagrisso
- Other names
- trastuzumab emtansine + osimertinibT-DM1 + osimertinib
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on ado-trastuzumab emtansine + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ado-trastuzumab emtansine + osimertinib.